Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 5 (2008), Issue 4 (April)

1. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
   Cancer Res, 68(7): 2321-8. [Abstract] [Full-text]
2. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism.
   Cancer Res, 68(7): 2275-85. [Abstract] [Full-text]
3. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.
   Cancer Res, 68(7): 2106-11. [Abstract] [Full-text]
4. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.
   Carcinogenesis, 29(4): 747-53. [Abstract] [Full-text]
5. Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers.
   Carcinogenesis, 29(4): 762-5. [Abstract] [Full-text]
6. Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs.
   Pharmacoepidemiol Drug Saf, 17(4): 322-7. [Abstract] [Full-text]
7. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.
   Cell, 133(1): 66-77. [Abstract] [Full-text]
8. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
   Am J Clin Oncol, 31(2): 133-9. [Abstract] [Full-text]
9. Predictive and prognostic value of FDG-PET.
   Cancer Imaging, 8: 70-80. [Abstract] [Full-text]
10. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    J Clin Oncol, 26(11): 1886-92. [Abstract] [Full-text]
11. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    J Clin Oncol, 26(11): 1879-85. [Abstract] [Full-text]
12. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
    J Clin Oncol, 26(11): 1871-8. [Abstract] [Full-text]
13. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk.
    Mol Carcinog, 47(5): 383-90. [Abstract] [Full-text]
14. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
    Mol Carcinog, 47(5): 326-37. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.